Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial

Summary Obesity is a frequent complication following liver transplantation and is insufficiently responsive to dietary and life style advice. We studied the safety of orlistat treatment in obese and overweight liver transplant recipients (n = 15) on a stable tacrolimus‐based immunosuppressive regime...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplant international 2006-12, Vol.19 (12), p.1000-1005
Hauptverfasser:	Cassiman, David, Roelants, Mieke, Vandenplas, Gerda, Van der Merwe, Schalk W., Mertens, Ann, Libbrecht, Louis, Verslype, Chris, Fevery, Johan, Aerts, Raymond, Pirenne, Jacques, Muls, Erik, Nevens, Frederik
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anti-Obesity Agents - adverse effects Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences cyclosporin drug interaction Drug Interactions Female General aspects Humans Lactones - adverse effects Lipids - blood Liver Transplantation - adverse effects Male Medical sciences Middle Aged Nephrology. Urinary tract diseases nonalcoholic fatty liver disease Obesity - drug therapy Overweight Pharmacology. Drug treatments Pilot Projects Prospective Studies tacrolimus Tacrolimus - therapeutic use weight loss
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!